About oprelvekin
Thrombopoietin receptor agonist
Used for
- Prevents severe low platelet counts in some adults receiving chemotherapy.
- Reduces the need for platelet transfusions in eligible patients.
Usual adult dose
50 micrograms/kg injected under the skin once daily, starting after chemotherapy; duration depends on blood counts and treatment protocol.
Common side effects
- Fluid retention, swelling, or shortness of breath
- Fast or irregular heartbeat
- Dizziness or fainting
- Injection-site reactions
Important warnings
- May cause serious fluid retention or heart failure.
- Can cause irregular heartbeat and other cardiovascular complications.
- May worsen fluid buildup in people with kidney or heart problems.
- Not for treating low platelets during leukemia treatment or for routine prevention.
Pregnancy
Human pregnancy information is limited; use only when clearly needed, as determined by a clinician.
Breastfeeding
It is not known whether oprelvekin passes into breast milk; breastfeeding safety is uncertain.
Interactions
- May increase fluid retention with medicines that also cause swelling.
- May affect medicines requiring close monitoring of blood counts.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.